De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Sonnet BioTherapeutics Holdings Balans Gezondheid

Financiële gezondheid criteriumcontroles 4/6

Sonnet BioTherapeutics Holdings heeft een totaal eigen vermogen van $2.6M en een totale schuld van $0.0, wat de schuld-eigenvermogensverhouding op 0% brengt. De totale activa en totale passiva bedragen respectievelijk $5.8M en $3.2M.

Belangrijke informatie

Verhouding schuld/eigen vermogen

US$0

Schuld

Rente dekkingsratio	n/a
Contant	US$3.55m
Aandelen	US$2.62m
Totaal verplichtingen	US$3.18m
Totaal activa	US$5.80m

Recente financiële gezondheidsupdates

Recent updates

Sonnet BioTherapeutics regains compliance with Nasdaq's minimum bid price requirement

Oct 04

Sonnet BioTherapeutics announces 1-for-14 reverse stock split

Sep 16

Sonnet gets clearance to start phase 1b/2a trial of SON-080 in Australia

Jul 22

We're A Little Worried About Sonnet BioTherapeutics Holdings' (NASDAQ:SONN) Cash Burn Rate

Dec 19

Sonnet Bio issued U.S. patent for its albumin binding technology

Jun 08

Sonnet shares rise after completing licensing agreement with New Life Therapeutics

May 03

Sonnet BioTherapeutics reports FY results

Dec 17

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( $5.1M ) SONN } overtreffen de korte termijn passiva ( $3.1M ).

Langlopende schulden: De kortetermijnactiva SONN ( $5.1M ) overtreffen de langetermijnschulden ( $68.8K ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: SONN is schuldenvrij.

Schuld verminderen: SONN heeft momenteel geen schulden, maar we kunnen geen vergelijking maken met 5 jaar geleden omdat we geen gegevens hebben over die periode.

Balans

Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: SONN heeft minder dan een jaar aan cash runway op basis van de huidige vrije kasstroom.

Voorspelling contante baan: SONN heeft minder dan een jaar aan kasmiddelen als de vrije kasstroom blijft dalen met historische percentages van 17.9 % per jaar.

Sonnet BioTherapeutics Holdings Balans Gezondheid

Financiële gezondheid criteriumcontroles 4/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Sonnet BioTherapeutics Regains Compliance with Nasdaq

Nasdaq Hearings Panel Grants Sonnet BioTherapeutics Holdings, Inc. an Exception Until October 15, 2024 to Regain Compliance with the $1.00 Minimum Bid Price Requirement

Nasdaq Determines to Delist Sonnet BioTherapeutics Holdings Securities

Nasdaq Determines to Delist Sonnet BioTherapeutics Holdings Securities

Sonnet BioTherapeutics Holdings Receives Non-Compliance Notice From Nasdaq

Sonnet BioTherapeutics Regains Nasdaq Minimum Bid Price Compliance

Recent updates

Sonnet BioTherapeutics Regains Compliance with Nasdaq

Sonnet BioTherapeutics Holdings, Inc Completes Enrollment in Phase 1 Study of SON-1010 (IL12-FHAB) as a Monotherapy (SB101) for the Treatment of Solid Tumors

Nasdaq Hearings Panel Grants Sonnet BioTherapeutics Holdings, Inc. an Exception Until October 15, 2024 to Regain Compliance with the $1.00 Minimum Bid Price Requirement

Nasdaq Determines to Delist Sonnet BioTherapeutics Holdings Securities

Nasdaq Determines to Delist Sonnet BioTherapeutics Holdings Securities

Consensus EPS estimates upgraded to US$1.95 loss

Sonnet Biotherapeutics Holdings, Inc. to Present SB221 as A Trial in Progress At the Asco 2024 Annual Meeting

Sonnet BioTherapeutics Holdings, Inc. Announces Updated Clinical Data for Son-1010 as Monotherapy or Combined with an Anti-Pd-L1, Along with an Increase in the Dose-Escalation Target

Consensus revenue estimates increase by 42%, EPS downgraded

Second quarter 2024 earnings released: EPS: US$0.079 (vs US$7.55 loss in 2Q 2023)

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Sonnet BioTherapeutics Holdings Receives Non-Compliance Notice From Nasdaq

Full year 2023 earnings: EPS and revenues exceed analyst expectations

New major risk - Share price stability

Sonnet BioTherapeutics Regains Nasdaq Minimum Bid Price Compliance

Sonnet Biotherapeutics Announces FDA Acceptance of the Company's IND for the SB221 Clinical Trial of SON-1010 Combined with Atezolizumab in the US

Third quarter 2023 earnings released: US$0.13 loss per share (vs US$1.82 loss in 3Q 2022)

Sonnet BioTherapeutics Holdings, Inc., Annual General Meeting, Aug 31, 2023

Sonnet Biotherapeutics Holdings, Inc. Announces Regulatory Approval for Initiation of A Clinical Trial of Son-1010 Combined with Atezolizumab

Founder recently bought US$83k worth of stock

Price target decreased by 13% to US$10.35

Consensus revenue estimates decrease by 50%, EPS upgraded

Sonnet BioTherapeutics Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $14.999777 million.

Sonnet BioTherapeutics Holdings, Inc. has completed a Follow-on Equity Offering.

Sonnet BioTherapeutics Announces Successful Completion of Two IND-Enabling Toxicology Studies with SON-1210 in Non-Human Primates

Sonnet BioTherapeutics Holdings, Inc. Announces Pharmacokinetic and Pharmacodynamic Data in A Phase 1 Dose-Escalation Trial of SON-1010

Price target decreased to US$25.00

Sonnet BioTherapeutics Holdings, Inc. Announces Interim Data in Two Phase 1 Dose-Escalation Trials of Son-1010

Nasdaq Listing Qualifications Staff Grants an Extension to Sonnet

Sonnet BioTherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Sonnet BioTherapeutics regains compliance with Nasdaq's minimum bid price requirement

Sonnet BioTherapeutics Holdings Inc. Appoints Lori McNeill to the Board of Directors

Sonnet BioTherapeutics Announces Progress in Two Phase 1 Dose-Escalation Trials of SON-1010

Sonnet BioTherapeutics announces 1-for-14 reverse stock split

Sonnet BioTherapeutics Holdings Receives Non-Compliance Letter from Nasdaq

Consensus forecasts updated

Sonnet BioTherapeutics Holdings, Inc. announced that it has received $2.25 million in funding

Sonnet gets clearance to start phase 1b/2a trial of SON-080 in Australia

Price target decreased to US$2.25

Sonnet BioTherapeutics Holdings, Inc., Annual General Meeting, Jun 02, 2022

Nasdaq Grants Extension to Sonnet BioTherapeutics Holdings Till October 03, 2022 to Regain Compliance

We're A Little Worried About Sonnet BioTherapeutics Holdings' (NASDAQ:SONN) Cash Burn Rate

Sonnet BioTherapeutics Holdings, Inc. Selects Novel Development Candidate After Completing Comparative Studies in a Mouse Melanoma Model

Sonnet BioTherapeutics Holdings, Inc. has completed a Follow-on Equity Offering.

High number of new directors

Sonnet Bio issued U.S. patent for its albumin binding technology

Sonnet shares rise after completing licensing agreement with New Life Therapeutics

New 90-day low: US$2.07

New 90-day high: US$3.10

Sonnet BioTherapeutics reports FY results

New 90-day high: US$2.98

New 90-day low: US$2.42

New 90-day low - US$2.46

New 90-day low - US$2.63

SONNET BioTherapeutics, Inc. completed the acquisition of Chanticleer Holdings, Inc. (NasdaqCM:BURG) in a reverse merger transaction.

Sonnet BioTherapeutics Holdings, Inc. completed the acquisition of Relief Therapeutics SA from Relief Therapeutics Holding AG (SWX:RLF).

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Analyse van de cashflow

Ontdek gezonde bedrijven